You can buy or sell Altimmune and other stocks, options, ETFs, and crypto commission-free!
Altimmune, Inc. Common Stock, also called Altimmune, is a clinical stage immunotherapeutic biotechnology company, which is focused on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. Read More Its portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
52 Week High
52 Week Low
Seeking AlphaMay 15
Altimmune, Inc. CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT) Q1 2019 Earnings Conference Call May 15, 2019 8:30 AM ET Company Participants Vipin Garg - Chief Executive Officer Will Brown - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Jerry Isaacson - ROTH Capital Operator Greetings, and welcome to the Altimmune First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation...
-$0.27 per share